Plain-English translation of NCT07331272 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called LUCAR-G79D for people with two serious autoimmune diseases: systemic lupus erythematosus (SLE) and idiopathic inflammatory myopathies (IIM). The medication is a type of 'CAR-T cell therapy,' which means doctors take some of your own immune cells, modify them in a lab to fight disease more effectively, and then put them back into your body. This study will check whether this treatment is safe and whether it helps reduce symptoms in patients whose disease hasn't improved with other treatments.
Lupus and inflammatory muscle diseases can be very difficult to treat, and many patients don't respond well to standard medicines. This medication represents a new approach — using your own body's immune cells as a personalized medicine — to help patients who have run out of other treatment options.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will first go through a screening phase to confirm you qualify. Then you will receive chemotherapy to prepare your immune system (called lymphodepleting chemotherapy). Next, you will receive an infusion of the modified immune cells — a single treatment given intravenously. After that, you will have follow-up visits so doctors can monitor how you respond, check for any side effects, and measure whether your symptoms improve. The study will track how the treatment moves through your body and how it affects your disease over time.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China